We are live on ! Find out more
CNTX icon

Context Therapeutics
CNTX

23 hedge funds and large institutions have $3.89M invested in Context Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

9% more capital invested

Capital invested by funds: $3.58M → $3.89M (+$311K)

5% more funds holding

Funds holding: 22 → 23 (+1)

2.13% more ownership

Funds ownership: 14.02% → 16.15% (+2.1%)

Holders
23
Holders Change
+1
Holders Change %
+4.55%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
7
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
+$260K
2
ABG
Ally Bridge Group
New York
+$82.1K
3
AAA
Affinity Asset Advisors
New York
+$69.3K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$21.3K
5
XT
XTX Topco
Cayman Islands
+$15K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$42.9K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$11.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
ABG
1
Ally Bridge Group
New York
$1.1M +$82.1K +72,555 +11%
Vanguard Group
2
Vanguard Group
Pennsylvania
$896K +$21.3K +18,791 +3%
AAA
3
Affinity Asset Advisors
New York
$497K +$69.3K +61,243 +23%
UOC
4
UBS O'Connor
Illinois
$447K +$260K +230,072 +351%
HighTower Advisors
5
HighTower Advisors
Illinois
$190K – – –
BCM
6
Bridgeway Capital Management
Texas
$160K – – –
MCCA
7
Mill Creek Capital Advisors
Pennsylvania
$158K – – –
Geode Capital Management
8
Geode Capital Management
Massachusetts
$147K -$11.3K -9,994 -9%
Northern Trust
9
Northern Trust
Illinois
$56.2K – – –
CHAM
10
Clear Harbor Asset Management
Connecticut
$54.4K – – –
State Street
11
State Street
Massachusetts
$49.7K – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$45K +$2.04K +1,800 +6%
SSWM
13
Sheets Smith Wealth Management
North Carolina
$30.2K – – –
XT
14
XTX Topco
Cayman Islands
$20K +$15K +13,259 New
Citadel Advisors
15
Citadel Advisors
Florida
$15.8K +$11.8K +10,438 New
AWM
16
Aspire Wealth Management
Massachusetts
$15.1K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$13.5K +$3.42K +3,026 +51%
Osaic Holdings
18
Osaic Holdings
Arizona
$2.27K – – –
FDCDDQ
19
Federation des caisses Desjardins du Quebec
Quebec, Canada
$604 – – –
RG
20
Retirement Group
California
$234 – – –
Wells Fargo
21
Wells Fargo
California
$163 +$1 +1 +0.9%
Bank of America
22
Bank of America
North Carolina
$151 – – –
JP Morgan Chase
23
JP Morgan Chase
New York
$24 +$18 +16 New
DCM
24
Difesa Capital Management
New York
– -$55.8K -34,878 Closed
Two Sigma Investments
25
Two Sigma Investments
New York
– -$42.9K -26,839 Closed

CNTX Hedge Fund Activity: Q3 2023 in Review

23 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q3 2023, worth a combined $3.89M — up 8.7% from $3.58M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CNTX positions and 2 closed out — a net gain of 1 holder — while 7 added to existing stakes and 1 trimmed.

The largest buyer was UBS O'Connor, adding an estimated $260K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $42.9K sold.

  • 23 institutional investors held Context Therapeutics (CNTX) as of Q3 2023, up from 22 in Q2 2023.
  • Funds reported $3.89M of Context Therapeutics stock for Q3 2023, up 8.7% quarter-over-quarter.
  • 3 funds opened new Context Therapeutics positions in Q3 2023 and 2 closed out, a net change of +1 holder.
  • The largest Context Therapeutics buyer in Q3 2023 was UBS O'Connor, an estimated $260K added.
  • The largest Context Therapeutics seller in Q3 2023 was Two Sigma Investments, an estimated $42.9K sold.

Based on aggregated 13F filings for Q3 2023.